ImmunityBio, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $38M | ↑+407.0% | — | — | — |
| 2025-09-30 | $32M | ↑+425.1% | $-67M | ↑+21.6% | -173.5% |
| 2025-06-30 | $26M | ↑+2423.9% | $-93M | ↑+31.2% | -269.8% |
| 2025-03-31 | $17M | ↑+41192.5% | $-130M | ↑+3.3% | -390.1% |
| 2024-12-31 | $8M | ↑+5333.1% | — | — | — |
| 2024-09-30 | $6M | ↑+7346.3% | $-86M | ↑+10.3% | -1314.3% |
| 2024-06-30 | $1M | ↑+2453.7% | $-135M | ↑+2.6% | -9487.4% |
| 2024-03-31 | $40K | ↓-88.9% | $-134M | ↓-15.1% | -237990.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$38M
↑+407.0% +$31M YoY
Net Income
$19M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
IBRX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyIBRX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics